Trials / Completed
CompletedNCT06667570
Efficacy of the SALFOAM 3% Method Compared to the Conventional Polidocanol Foam Method (Tessari Method) for Treating Lower Limb Varicose Veins
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Lidiane Rocha · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This clinical trial aims to assess the efficacy and safety of the SALFOAM 3% method, which involves saline wash, polidocanol 3% foam injection, and extrinsic compression using Lidstop®, in comparison with the conventional Tessari method for the treatment of lower limb varicose veins. The primary objective is to determine whether the SALFOAM 3% method results in better or equivalent vein occlusion rates and fewer adverse effects, such as hyperpigmentation, compared to the standard treatment.
Detailed description
Chronic venous disease (CVD) is prevalent in approximately 38% of the adult population in Brazil, posing significant public health challenges due to its potential complications, including ulcerations and reduced quality of life. The SALFOAM 3% method is a novel approach that combines saline wash prior to polidocanol 3% foam sclerotherapy and extrinsic compression with Lidstop®, aiming to improve outcomes by reducing adverse effects such as hyperpigmentation and enhancing patient quality of life. This randomized controlled trial will compare the efficacy, safety, and quality of life outcomes of patients treated with the SALFOAM 3% method versus those treated with the conventional Tessari method for lower limb varicose veins.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | SALFOAM 3% | * Drug: Polidocanol 3% * Device: Lidstop® |
| PROCEDURE | Control Group | * Drug: Polidocanol 3% * Device: Standard compression with dental roll and elastic stockings |
Timeline
- Start date
- 2024-10-25
- Primary completion
- 2025-02-14
- Completion
- 2025-02-14
- First posted
- 2024-10-31
- Last updated
- 2025-11-25
Locations
1 site across 1 country: Brazil
Source: ClinicalTrials.gov record NCT06667570. Inclusion in this directory is not an endorsement.